94% of eligible adults aren't getting the nationally recommended screening1
Lung cancer is the leading cause of cancer death in the United States.2 15.1 million Americans are at an elevated risk for the disease* but only 6 percent get recommended screening with a low-dose CT scan.1,3 While lung cancer is most treatable when caught in its early stages, most people do not initially show any signs or symptoms.
We look forward to meeting you!
DELFI will be presenting data and information on FirstLook and our fragmentomics approach at
upcoming industry meetings:
October 8-11, 2023, Honolulu
October 8-11, 2023, Las Vegas
DELFI is committed to bringing additional products to market that address major unmet medical needs with strong demand for new solutions. We are taking a scientifically rigorous and sustainable approach to ongoing innovation with our DELFI platform.
DELFI has published promising proof-of-concept data in other cancer types. As our platform is designed to be flexibly deployed, we are also building a body of evidence to show how the DELFI platform can be used for monitoring and minimal residual disease (MRD) applications.
References: 1. American Lung Association. New Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives. Nov. 2022. 2. NIH National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. 3. Meza R et al. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography Modeling Study for the US Preventive Services Task Force. JAMA. 2021;325(10):988-997. 4. FirstLook Performance: Data on File.
The FirstLook Lung test is a laboratory-developed test. It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high complexity clinical tests. This test is used for clinical purposes. It should not be regarded as investigational or for research.
FirstLook is a trademark of DELFI Diagnostics, Inc. used worldwide.